Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up

Delefortrie, Quentin; Schatt, Patricia; Grimmelprez, Alexandre; Gohy, P; Deltour, D; Collard, Geneviève; Vankerkhoven, P.

doi:10.1016/j.clinbiochem.2015.10.010

Cited by 22 publications

(27 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CI, confidence interval; SE, standard error. Along with non-standardisation between the different faecal calprotectin assays, pre-analytical issues of faecal calprotectin analyses can contribute to the (often large) variation in faecal calprotectin concentrations between different assays [6,7,10,26]. In this study, all faecal samples where appropriately homogenised and weighed before extraction.…”

Section: Discussionmentioning

confidence: 99%

“…50 μg/g) but specificity at this cut-off value differed between the assays (ranging from 58.4% to 78.5%). This, together with the fact that there is not yet a standardised method for faecal calprotectin measurement, indicates that recommended cut-off values would have to be determined depending on the clinical setting they are used in [10].…”

Section: Methodsmentioning

confidence: 99%

“…Consequently, faecal calprotectin concentration may be related to inflammation of the bowel mucosa in IBD. Despite some analytical and pre-analytical drawbacks [6][7][8][9][10], encouraging data have recently been published about the clinical efficacy of this biomarker for monitoring disease activity, response to treatment and relapse [11,12]. In addition, faecal calprotectin is resistant to bacterial degradation, being stable in stool for up to 3 days at room temperature, which adds more benefits to its use as a laboratory marker [13].…”

Section: Introductionmentioning

confidence: 99%

“…Faecal calprotectin extraction: To prevent pre-analytical variation [6,10], all samples were weighted and extracted with the Smart Prep Extraction Device (Roche Diagnostics, Mannheim, Germany) in accordance with the manufacturer's instructions but using the different company specific faecal calprotectin buffers. Extractions were performed in different batches, immediately followed by calprotectin analyses.…”

Section: Measurement Of Faecal Calprotectinmentioning

confidence: 99%

“…In addition, results are rapidly available, which allows quick clinical decision making. However, as laboratories are being consolidated, more automated assays such as enzyme-linked immunoassays (ELISA) [7,22,23], chemiluminescence immunoassays (CLIA), fluoro enzyme immunoassays (FEIA) and particle enhanced turbidimetric immunoassays (PETIA) for the measurement of faecal calprotectin have been introduced [10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Oyaert

Boel

Jacobs

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: We evaluated the analytical performance of six different faecal calprotectin immunoassays together with their diagnostic accuracy in the discrimination between functional and organic bowel disorders. Methods: The faecal samples were obtained from inflammatory bowel disease patients (n = 27) at the time of diagnosis [Crohn's disease (n = 15), colitis ulcerosa (n = 12)], gastroenterologic disease control patients (n = 52) and rheumatologic disease control patients (n = 26). All individuals included in the study underwent a concurrent ileocolonoscopy. Analytical performance (imprecision, accuracy, carry-over, correlation and agreement) and diagnostic accuracy (sensitivity, specificity, likelihood ratios) of the different assays were evaluated. Results: All methods demonstrated good analytical performance, but within-run and total imprecision varied depending on the assay methodology used. Using Passing Bablok and Bland-Altman analyses, low quantitative agreement was observed between the assays. All assays showed excellent diagnostic accuracy, with areas under the receiver operating characteristic curves (ROC) ranging from 0.974 to 0.998. The AUCs were not significantly different between assays (p > 0.05). Diagnostic sensitivity at the

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Measurement Of Faecal Calprotectinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Oyaert

Boel

Jacobs

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

Non‐invasive detection of Crohn's Disease with label‐free detection of calprotectin by impedimetric aptasensor

Aslan,

Ertugrul Uygun,

Uygun

et al. 2023

Electroanalysis

View full text Add to dashboard Cite

show abstract

Evaluation of a fluorescent immunochromatography test for fecal calprotectin

Zhao

Dong

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Fecal calprotectin (FC) is widely used to discriminate between patients with inflammatory diseases such as inflammatory bowel disease (IBD) and functional diseases such as irritable bowel syndrome (IBS). ELISA is a time‐consuming method for the measurement of FC, whereas a fluorescent immunochromatography test can obtain results in around 30 minutes and thus enables a rapid response to clinical decision. Methods Two methods, the Proglead® calprotectin (FC Proglead) and the BÜHLMANN fCAL® ELISA (FC BÜHLMANN), were used to quantitatively examine FC in 111 stool samples. The comparison and bias estimation of both assays were assessed using CLSI EP09c protocol. Results The two methods were highly correlated (rho = .96). Deming regression was employed to calculate the regression equation, with a slope of 1.01 and an intercept of −4.98 μg/g. The estimated median bias (FC Proglead − FC BÜHLMANN) was −4.19 μg/g with the 95% limits of agreement (−55.59 to 47.21 μg/g), and the estimated median percent bias was −8.71% with the 95% limits of agreement (−50.31% to 32.90%). There was 4.50% (5/111) of values outside the 95% limits of agreement. Percent biases at the FC cutoff values of 50 and 200 μg/g between both methods evaluated by Deming regression were 8.96% and 1.49%, respectively. The biases were all less than the acceptable standard (10%). And, 99.10% of FC results were in agreement between both methods (kappa = .99, P < .001). Conclusions FC Proglead may be used as a suitable alternative to FC BÜHLMANN for the disease activity assessment for patients with IBD, considering its convenience and shorter turnaround time.

show abstract

Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up

Cited by 22 publications

References 19 publications

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Non‐invasive detection of Crohn's Disease with label‐free detection of calprotectin by impedimetric aptasensor

Evaluation of a fluorescent immunochromatography test for fecal calprotectin

Contact Info

Product

Resources

About